TCG Crossover Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

TCG Crossover Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,000,000	Closed	-$10.5M	–	24
2022 Q4	$10.5M	Hold	1,000,000	–	–	1.85%	16
2022 Q3	$7.76M	Hold	1,000,000	–	–	2.33%	14
2022 Q2	$5.25M	Buy	+1,000,000	New	+$6.29M	2.23%	15

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCG Crossover Management's MLTX Position: Q1 2023 in Review

TCG Crossover Management sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2023, closing a stake of 1,000,000 shares — an estimated $10.5M sold.

TCG Crossover Management first reported a position in MLTX in Q2 2022 and held it in 3 quarters. The position peaked at $10.5M in Q4 2022. 43 funds tracked by Wall St. Rank hold MLTX as of Q1 2023.

TCG Crossover Management reported no remaining MoonLake Immunotherapeutics position as of Q1 2023 after selling out during the quarter.
TCG Crossover Management sold 1,000,000 MoonLake Immunotherapeutics shares in Q1 2023, an estimated $10.5M.
TCG Crossover Management first reported a position in MoonLake Immunotherapeutics in Q2 2022 and held it in 3 quarters.
TCG Crossover Management's MoonLake Immunotherapeutics position peaked at $10.5M in Q4 2022.
43 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2023.

Based on TCG Crossover Management's 13F filing for Q1 2023, filed 15 May 2023.